

Financial Tear Sheet

Corporate Profile

Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.

Lefamulin

Nabriva's lead pleuromutilin product candidate, lefamulin, is being studied for the treatment of moderate to severe CABP. We have completed the LEAP 1 Phase 3 trial ...

Share Performance

Last	Change (%)	Volume	Open
9.79 USD	▼ -0.02 -(0.20%)	11,250	9.91

Recent News

12/13/17

[Nabriva Therapeutics Added to NASDAQ Biotechnology Index](#)

12/04/17

[Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults](#)

11/30/17

[Nabriva Therapeutics to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/12/17	S-8

Management

Colin Broom	Chief Executive Officer
Robert Crotty	General Counsel

12/01/17	4	Steven Gelone	Chief Scientific Officer and Head of Business Development
11/09/17	10-Q		
11/09/17	8-K	Francesco Maria Lavino	Chief Commercial Officer
		Gary Sender	Chief Financial Officer
		David Garrett	Vice President, Corporate Controller and Head of Investor Relations
		Leanne Gasink	Vice President, Clinical Research and Development
		Werner Heilmayer	Vice President CMC & IP
		Ernie Kelly	Vice President Quality
		Thomas Lembck	Chief Information Officer
		William Sargent	Vice President, Commercial Strategy and Access

Data provided by Nasdaq. Minimum 15 minutes delayed.